| Identifier | HPI103592 |
| Interaction | p53 <==> bcl-2 |
| Role & State | --- |
| Interaction Type | IT:0000099,formation; IT:0000114,activation; |
| Biological Process | --- |
| Biological Function | --- |
| Subcelluar Location | --- |
| Detection Method | --- |
| Reference | 10383693_0, p53 but not bcl-2 is expressed by most cholangiocarcinomas: a study of 28 cases.
|
| Reference | 15110228_11, Antigenic activation of B cells, together with oncogenic events, including p53 inactivation and bcl-2 activation, may play important roles in B cell monoclonal proliferation and malignant transformation.
|
| Reference | 16767924_5, In the multivariate analysis p53 accumulation and bcl-2 expression emerged as independent predictors respectively of worse and better clinical outcome also in Dukes' B stage identifying patients at higher risk to develop liver metastases..
|
| Reference | 17191126_5, Bax expression was up-regulated following high levels of p53 expression, while bcl-2 expression was not altered by the level of p53 expression.
|
| Reference | 18854271_7, Our data show that p53, bcl-2, bax, and COX-2 have an important role in the pathogenesis of cholangiocarcinomas.
|
| Reference | 9821791_5, The expression of p53 was observed in both hepatocellular carcinoma and metastatic liver cancer, but bcl-2 expression was observed neither in hepatocellular carcinoma nor in metastatic liver cancer.
|
| |
|